tbuckley/cabot-search huggingface dataset:
ESEN : uma comparação dos programas de vacinação – Terceira parte: sarampo, parotidite e rubéola
Authors: D Lévy-Bruhl, R G Pebody, I Veldhuijzen, M Valenciano, K Osborne
Journal: Eurosurveillance (1998)

Este e o ultimo de uma serie de tres artigos nos quais sao comparados programas de vacinacao, calendarios de imunizacao, coberturas das vacinacoes e o impacto epidemiologico da imunizacao contra a difteria, tosse convulsa, sarampo, parotidite e rubeola em oito paises (Dinamarca, Inglaterra e Pais de Gales, Finlândia, Franca, Alemanha, Italia, Suecia e Holanda). Esta analise foi efectuada dentro da Rede Europeia de Sero-Epidemiologia (European Sero-Epidemiology Network (ESEN)), com base na UE (1). A metodologia da analise, as caracteristicas dos programas de imunizacao e os resultados para a difteria e tosse convulsa foram apresentados nos dois numeros anteriores da serie (2,3). Este artigo apresenta os resultados para o sarampo, parotidite e rubeola (SPR).
Aldosterone Is Essential for Angiotensin II-Induced Upregulation of Pendrin
Authors: Daigoro Hirohama, Nobuhiro Ayuzawa, Kohei Ueda, Mitsuhiro Nishimoto, Wakako Kawarazaki, Atsushi Watanabe, Tatsuo Shimosawa, Takeshi Marumo, Shigeru Shibata, Toshiro Fujita
Journal: Journal of the American Society of Nephrology (2017)

The renin-angiotensin-aldosterone system has an important role in the control of fluid homeostasis and BP during volume depletion. Dietary salt restriction elevates circulating angiotensin II (AngII) and aldosterone levels, increasing levels of the Cl − /HCO 3 − exchanger pendrin in β -intercalated cells and the Na + -Cl − cotransporter (NCC) in distal convoluted tubules. However, the independent roles of AngII and aldosterone in regulating these levels remain unclear. In C57BL/6J mice receiving a low-salt diet or AngII infusion, we evaluated the membrane protein abundance of pendrin and NCC; assessed the phosphorylation of the mineralocorticoid receptor, which selectively inhibits aldosterone binding in intercalated cells; and measured BP by radiotelemetry in pendrin-knockout and wild-type mice. A low-salt diet or AngII infusion upregulated NCC and pendrin levels, decreased the phosphorylation of mineralocorticoid receptor in β -intercalated cells, and increased plasma aldosterone levels. Notably, a low-salt diet did not alter BP in wild-type mice, but significantly decreased BP in pendrin-knockout mice. To dissect the roles of AngII and aldosterone, we performed adrenalectomies in mice to remove aldosterone from the circulation. In adrenalectomized mice, AngII infusion again upregulated NCC expression, but did not affect pendrin expression despite the decreased phosphorylation of mineralocorticoid receptor. By contrast, AngII and aldosterone coadministration markedly elevated pendrin levels in adrenalectomized mice. Our results indicate that aldosterone is necessary for AngII-induced pendrin upregulation, and suggest that pendrin contributes to the maintenance of normal BP in cooperation with NCC during activation of the renin-angiotensin-aldosterone system by dietary salt restriction.
Implementation of policies to protect planetary health
Authors: Subhrendu K Pattanayak, Andy Haines
Journal: The Lancet Planetary Health (2017)

Extensive evidence exists that human health and civilisation depends on flourishing natural systems.1 The Rockefeller–Lancet Commission on planetary health summarised how climate change, biodiversity loss, freshwater depletion, and air and water pollution threaten to reverse advances in human health and increase health inequities worldwide.2 For example, increasing carbon dioxide concentrations and declines in animal pollinators will exacerbate micronutrient deficiencies and risks of non-communicable disease.
Scaffold Composition Determines the Angiogenic Outcome of Cell‐Based Vascular Endothelial Growth Factor Expression by Modulating Its Microenvironmental Distribution
Authors: Emanuele Gaudiello, Ludovic Melly, Giulia Cerino, Stefano Boccardo, Sasan Jalili‐Firoozinezhad, Lifen Xu, Friedrich Eckstein, Ivan Martin, Beat A. Kaufmann, Andrea Banfi, Anna Marsano
Journal: Advanced Healthcare Materials (2017)

Abstract Delivery of genetically modified cells overexpressing Vascular Endothelial Growth Factor (VEGF) is a promising approach to induce therapeutic angiogenesis in ischemic tissues. The effect of the protein is strictly modulated by its interaction with the components of the extracellular matrix. Its therapeutic potential depends on a sustained but controlled release at the microenvironmental level in order to avoid the formation of abnormal blood vessels. In this study, it is hypothesized that the composition of the scaffold plays a key role in modulating the binding, hence the therapeutic effect, of the VEGF released by 3D‐cell constructs. It is found that collagen sponges, which poorly bind VEGF, prevent the formation of localized hot spots of excessive concentration, therefore, precluding the development of aberrant angiogenesis despite uncontrolled expression by a genetically engineered population of adipose tissue‐derived stromal cells. On the contrary, after seeding on VEGF‐binding egg‐white scaffolds, the same cell population caused aberrantly enlarged vascular structures after 14 d. Collagen‐based engineered tissues also induced a safe and efficient angiogenesis in both the patch itself and the underlying myocardium in rat models. These findings open new perspectives on the control and the delivery of proangiogenic stimuli, and are fundamental for the vascularization of engineered tissues/organs.
Vigilancia centinela de enfermedades de transmisión sexual en Italia
Authors: M Giuliani, B Suligoi
Journal: Eurosurveillance (1998)

Las declaraciones obligatorias sugieren que la incidencia de la infeccion gonococica y sifilis ha disminuido en los ultimos 30 anos en Italia, al igual que ha ocurrido en otros paises desarrollados (figura 1). A pesar de ello, durante la decada de los ochenta, las tasas anuales de notificacion en Italia fueron entre 15 y 50 veces menores que en otros paises europeos, lo que sugiere que la informacion del sistema de declaracion obligatoria no reflejaba la verdadera incidencia de estas dos enfermedades.
Effect of iodine supplementation in pregnant women on child neurodevelopment: a randomised, double-blind, placebo-controlled trial
Authors: Sueppong Gowachirapant, Nidhi Jaiswal, Alida Melse-Boonstra, Valeria Galetti, Sara Stinca, Ian Mackenzie, Susan Thomas, Tinku Thomas, Pattanee Winichagoon, Krishnamachari Srinivasan, Michael B Zimmermann
Journal: The Lancet Diabetes & Endocrinology (2017)
A phamacoeconomic analysis of personalized dosing versus fixed dosing of pembrolizumab in first-line PD-L1 positive non-small cell lung cancer.
Authors: Daniel A. Goldstein, Noa Gordon, Michal Davidescu, Moshe Leshno, Conor Ernst Steuer, Nikita Patel, Salomon M. Stemmer, Alona Zer
Journal: Journal of Clinical Oncology (2017)

9013 Background: In October 2016 pembrolizumab became the new standard of care for first-line treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death ligand 1 in at least 50% of cells. The FDA recommended dose is 200mg every three weeks. Multiple studies have demonstrated equivalent efficacy with weight-based doses between 2mg/kg to 10 mg/kg. The objective of this study was to compare the economic impact of using personalized dosing (2mg/kg) versus fixed dosing (200mg) in the first line setting of mNSCLC. Methods: We performed a budget impact analysis from the US societal perspective to compare fixed dosing with personalized dosing. We calculated the target population and weight of patients that would be treated with pembrolizumab annually in the first-line setting. Using survival curves from the KEYNOTE 024 trial with Weibull extrapolation we estimated the mean number of cycles that patients would receive. Using the Medicare average sales price we calculated the difference in cost between personalized and fixed dosing. Results: Our base case model demonstrates that the total annual cost of pembrolizumab with fixed dosing is US$ 3,440,127,429, and with personalized dosing it is US$ 2,614,496,846. The use of personalized dosing would lead to a 24% annual saving of US$ 825,630,583 in the United States. Conclusions: Personalized dosing of pembrolizumab may have the potential to save approximately 0.825 billion dollars annually in the United States, likely without impacting outcomes. This option should be considered for the first-line management of PD-L1 positive advanced lung cancer.
Consultants might be less available on Black Wednesday
Authors: Raphael PZ Rifkin-Zybutz, Thomas Taylor, Jonathan I Spencer
Journal: BMJ (2017)

The start date for new junior doctors is referred to as “Black Wednesday,” coined after a 2009 study showed that patients admitted to hospital in the first week in August had a 6-8% higher mortality rate than those admitted in the last week of July.1 As The …
Management of hypertension in obstructive sleep apnoea: predicting blood pressure reduction under continuous positive airway pressure
Authors: Renaud Tamisier, Patrick Lévy
Journal: European Respiratory Journal (2017)

Hypertension affects a quarter of the adult population and remains a leading cause of cardiovascular mortality, accounting for 13.5% of all deaths. Half of all strokes and ischaemic heart disease events are attributable to high blood pressure (BP) [1, 2]. Most patients exhibit Grade-I hypertension (systolic BP of 140 to 159 mmHg and/or diastolic BP of 90 to 99 mmHg) without co-existing cardiovascular disease. An active reduction of BP results in a significant reduction in stroke and death [3]. 24-hour BP measurement and nocturnal heart rate may help to predict BP response to CPAP. Further studies are needed <http://ow.ly/YBBn30fgpWZ>
L'uso del virus del vaiolo come arma biologica: situazione della vaccinazione in Francia
Authors: D Lévy-Bruhl, N Guérin
Journal: Eurosurveillance (2001)

Nell'ambito dei piani di lotta al bioterrorismo, il Ministro della Sanita francese ha chiesto all'Institut de Veille Sanitaire di valutare il rischio epidemico in caso di introduzione del virus del vaiolo, e di proporre delle raccomandazioni sulle eventuali strategie vaccinali da mettere in atto. E' stata condotta un'analisi beneficio/rischio di differenti scenari, inclusa la vaccinazione dell'intera popolazione francese, a livelli diversi di gravita di minaccia terroristica. In base a questa analisi si puo concludere che nella situazione attuale non sembra giustificata nessuna azione vaccinale. Anche in caso che si avveri una minaccia, si deve dare priorita alla vaccinazione del personale sanitario in prima linea, e in particolare degli operatori in contatto diretto con i casi.
Difficulties in Defining and Measuring Cancer-Related Fatigue
Authors: Lawrence Berk
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Nivolumab and ISA 101 HPV vaccine in incurable HPV-16+ cancer
Authors: B. Glisson, E. Massarelli, W.N. William, F.M. Johnson, M.S. Kies, R. Ferrarotto, M. Guo, S.A. Peng, J.J. Lee, H. Tran, Y.U. Kim, C. Haymaker, C. Bernatchez, M. Curran, B. Sanchez Espiridion, J. Rodriguez Canales, I.I. Wistuba, S. van der Burg, J. Wang, C. Melief
Journal: Annals of Oncology (2017)
Phase 2, multicenter, single-arm, open label study evaluating the combination of daratumumab + cyclophosphamide, bortezomib and dexamethasone (Dara-CyBorD) in previously untreated and relapsed patients (pts) with multiple myeloma (MM)
Authors: M. Sharma, L. Ey, H. Parros, S. Murphy, M. Darif, A. Londhe, J. Ukropec, M. Qi, Y. Lutska, T. Lin, S. Gunawardena
Journal: Annals of Oncology (2017)
Clinical benefit of randomized controlled trials (RCT) supporting US Food and Drug Administration (FDA) conversion from accelerated to full approval
Authors: M. Borrell Puy, C. Molto Valiente, A. Ocana Fernandez, A. Templeton, B. Seruga, I. Gich, A. Barnadas, E. Amir, A. Tibau
Journal: Annals of Oncology (2017)
Integrative DNA methylome and miRNA transcriptome analysis for new biomarker discovery in entero-pancreatic neuroendocrine tumours (EP-NETS)
Authors: J. Barriuso, A. Lamarca, V. Heredia, L. Guerra-Pastrian, C. Alvarez-Escola, J. Castell, A. Custodio, M. Miguel, M. Mendiola, J. Feliu
Journal: Annals of Oncology (2017)
PROREPAIR-B: A prospective cohort study of DNA repair defects in metastatic castration resistant prostate cancer (mCRPC)
Authors: E. Castro Marcos, N. Romero Laorden, J.M. Piulats Rodriguez, A. del Pozo, M.I. Sáez, A. Medina Colmenero, J. Puente, J.C. Silla-Castro, R. Lozano Mejorada, I. Garcia-Carbonero, L. Rivera, M.J. Mendez Vidal, R. Morales Barrera, E.M. Fernandez Parra, Y. Cendón Flórez, P. Borrega, M.A. Gonzalez Del Alba Baamonde, C. Pritchard, P. Lapunzina, D. Olmos Hidalgo
Journal: Annals of Oncology (2017)
Toxicity Profiles in Patients Using Bortezomib for Multiple Myeloma: Korean Multicenter Analysis.
Authors: Soo-Mee Bang, Jae Hoon Lee, Sung-Soo Yoon, Seonyang Park, Chang-Ki Min, Cheolwon Suh, Sang Kyun Sohn, Yoo-Hong Min, Je-Jung Lee, Kihyun Kim, Chu-Myong Seong, Hwi-Joong Yoon, Deog-Yeon Jo, Kyung Hee Lee, Na-Ri Lee
Journal: Blood (2005)
Notch pathway inhibition with LY3039478 in adenoid cystic carcinoma (ACC).
Authors: Caroline Even, Ulrik Niels Lassen, Jaime R. Merchan, Christophe Le Tourneau, Jean-Charles Soria, Charles Ferte, Jon Thomas Diener, Eunice Yuen, Claire Smith, Gerard Joseph Oakley, Karim A. Benhadji, Christophe Massard
Journal: Journal of Clinical Oncology (2017)

6024 Background: ACCs have high levels of Notch-1 receptor expression and activation. LY3039478 (LY) is an orally bioavailable selective Notch inhibitor (Notch 1-4). Here we report on safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of LY in patients (pts) with ACC. Methods: Ongoing, multi-part, phase I trial enrolled pts with advanced or metastatic ACC, measurable disease, ECOG ≤1, and baseline tumor tissue. Eligible pts received LY 50 mg three times per week (TIW), on a 28-day cycle until disease progression. Safety assessments were based on CTCAE V4.0. Tumor responses were assessed using RECIST 1.1. Primary objectives are to confirm the recommended phase II dose of LY and document antitumor activity. Secondary objectives are safety and toxicity, PK and progression-free survival (PFS). Exploratory objectives include assessment for PET metabolic responses. Results: 22 pts have been enrolled and received LY 50mg TIW (13 men, 9 women; median age 60, range 41-82). All pts had metastatic disease; median treatment duration was 3 cycles (range 1-10) with 6 pts continuing on treatment. One pt had an unconfirmed partial response. Disease control rate (DCR) was 16/22 (73%), of which 4 pts had stable disease ≥ 6 months. In the overall group (n = 22) median PFS (mPFS) was 5.3 months (95% CI: 2.4, NE). mPFS was 7.7 (95% CI: 4.0, NE) for pts in second line (n = 7), while mPFS was 2.4 (95% CI: 1.1, NE) for pts in third line or more (n = 9). In pts without prior systemic therapy (n = 6) mPFS could not be estimated since 4 of those patients were censored. In preliminary analysis, 14 pts were assessed by PET, with 2 (14%) achieving partial metabolic response. Most frequent related adverse events (all grades) occurring in ≥20% of pts included diarrhea (55%), fatigue (45%), vomiting (36%), decreased appetite (27%), dry mouth (27%), and dry skin (23%). Grade 3/4 related treatment-emergent adverse events observed in more than one pt were diarrhea (n = 3) and squamous cell carcinoma of skin (n = 2). PK was assessed in 17 pts, with peak concentrations occurring approximately 2 hours post-dose. Biomarker and histologic analyses of pre and post treatment biopsies will be presented. Conclusions: LY showed activity (73% DCR) in ACC with a manageable safety profile. Clinical trial information: NCT01695005.
Un'epidemia nazionale di morbillo in Svizzera nel 1997: conseguenze sull'eliminazione del morbillo entro il 2007
Authors: W J Paget, H Zimmermann, H Vorkauf
Journal: Eurosurveillance (2000)

In Svizzera dal giugno 1986 i casi clinici di morbillo vengono notificati allo Swiss Sentinel Surveillance Network -SSSN (Sentinella) (1) e dal gennaio 1988 le infezioni di morbillo vengono monitorate dal sistema nazionale di notifica di laboratorio. Questi due sistemi di sorveglianza costituiscono uno dei principali strumenti per valutare l'attivita vaccinale contro morbillo, parotite e rosolia (MPR). La vaccinazione contro il morbillo e raccomandata dal 1976 e, nel 1987, lo Swiss Advisory Board for Immunisation e lo Swiss Federal Office of Public Health (SFOPH) hanno lanciato una campagna nazionale di vaccinazione MPR. Dal 1996, sono state raccomandate due dosi di vaccino MPR - all'eta di 15 mesi e prima di cominciare la scuola (tra i quattro e i sette anni) – per tutti i bambini.
Cold-Induced Thermogenesis Depends on ATGL-Mediated Lipolysis in Cardiac Muscle, but Not Brown Adipose Tissue
Authors: Renate Schreiber, Clemens Diwoky, Gabriele Schoiswohl, Ursula Feiler, Nuttaporn Wongsiriroj, Mahmoud Abdellatif, Dagmar Kolb, Joris Hoeks, Erin E. Kershaw, Simon Sedej, Patrick Schrauwen, Guenter Haemmerle, Rudolf Zechner
Journal: Cell Metabolism (2017)

Fatty acids (FAs) activate and fuel UCP1-mediated non-shivering thermogenesis (NST) in brown adipose tissue (BAT). Release of FAs from intracellular fat stores by adipose triglyceride lipase (ATGL) is considered a key step in NST. Accordingly, the severe cold intolerance of global ATGL knockout (AKO) mice has been attributed to defective BAT lipolysis. Here we show that this conclusion is incorrect. We demonstrate that although the BAT-specific loss of ATGL impairs BAT lipolysis and alters BAT morphology, it does not compromise the β3-adrenergic thermogenic response or cold-induced NST. Instead, NST depends on nutrient supply or lipolysis in white adipose tissue during fasting, suggesting that circulating energy substrates are sufficient to fuel NST. Cold intolerance in AKO mice is not caused by BAT dysfunction as previously suspected but by severe cardiomyopathy. We conclude that functional NST requires adequate substrate supply and cardiac function, but does not depend on ATGL-mediated lipolysis in BAT.
Abstract 14909: Difference of Five-year Clinical Outcomes of Multi-overlapped Stents for Treatment of Long Lesions Between First and Second Generation Drug Eluting Stents
Authors: Koji Yasumoto, Masami Nishino, Motoki Yasunaga, Kyosuke Yanagawa, Yutaka Matsuhiro, Hitoshi Nakamura, Keisuke Yasumura, Naotaka Okamoto, Akihiro Tanaka, Naoki Mori, Daisuke Nakamura, Masamichi Yano, Nobuhiko Makino, Yasuyuki Egami, Ryu Shutta, Jun Tanouchi
Journal: Circulation (2016)

Background: Previous studies indicated that long coronary lesions are one of the key predictors of drug-eluting stent (DES) failure, but long-term clinical outcomes of multi-overlapped long DESs ar...
Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study
Authors: Xavier Mariette, Frauke Förger, Bincy Abraham, Ann D Flynn, Anna Moltó, René-Marc Flipo, Astrid van Tubergen, Laura Shaughnessy, Jeff Simpson, Marie Teil, Eric Helmer, Maggie Wang, Eliza F Chakravarty
Journal: Annals of the Rheumatic Diseases (2017)

There is a need for effective and safe treatment during pregnancy in women with chronic inflammatory diseases. This study evaluated placental transfer of certolizumab pegol (CZP), an Fc-free anti-tumour necrosis factor drug, from CZP-treated pregnant women to their infants.
Clinical implications of genomic variants identified in over 30,000 advanced-stage cancer patients by next-generation sequencing of circulating tumor DNA
Authors: S.K. Pal, C. Brooks, D. Chudova, J. Odegaard, D.R. Gandara, P. Mack, S. Mortimer, K. Banks, R.J. Nagy, A. Baca, R. Lanman, H. Eltoukhy, A. Talasaz
Journal: Annals of Oncology (2017)
Trials and Tribulations of CETP Inhibitors
Authors: Alan R. Tall, Daniel J. Rader
Journal: Circulation Research (2017)

The development of CETP (cholesteryl ester transfer protein) inhibitors has had a long and difficult course with 3 compounds failing in phase III clinical trials. Finally, the REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid modification) trial has shown that the CETP inhibitor anacetrapib decreased coronary heart disease when added to statin therapy. Although the result is different to earlier studies, this is likely related to the size and duration of the trial. The benefit of anacetrapib seems to be largely explained by lowering of non-HDL-C (high-density lipoprotein cholesterol), rather than increases in HDL-C. Although the magnitude of benefit for coronary heart disease appeared to be moderate, in part this may have reflected aspects of the trial design. Anacetrapib treatment was associated with a small increase in blood pressure, but was devoid of major side effects and was also associated with a small reduction in diabetes mellitus. Treatment with CETP inhibitors, either alone or in combination with statins, could provide another option for patients with coronary disease who require further reduction in LDL (low-density lipoprotein) and non-HDL-C.